Ann: Kazia releases preliminary Cantrixil Phase I data, page-7

Without being a scientist the results seem good. Signs of efficacy at low doses. Very late though given the company model was to be project managers only.

Does everyone read it to be 5 evaluable patients 3 with SD plus 1 with PR?

Almost 2 years for just the dose escalation maybe a further 12 months for the rest assuming they can find the patients.